Although prostate-specific antigen (PSA) testing remains the most widely used tool for PCa screening, its suboptimal specificity and moderate sensitivity, especially within the diagnostic gray zone of 4-10 ng/mL-frequently leads to unnecessary prostate biopsies, overdiagnosis, and overtreatment. The gene discussed is KLK3; the disease is posterior cortical atrophy.